Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Tessa Tan-Torres Edejer Global Programme on
Evidence for Health Policy, World Health Organisation, CH-1211 Geneva
27, Switzerland
tantorrest@who.ch
| The first 150 words of the full text of this article appear below. |
The new phase of North-South research collaboration was
caught in a snapshot published recently in a popular weekly
newsmagazine.1 The picture is that of a participant in an
AIDS study in Guatemala City. He looks jaunty, even confident. In 1997, he participated in a "life-and-death lottery," as the article is
entitled, and beat the odds to be entered into a Merck drug trial of
different doses of a triple cocktail containing their new drug,
Crixivan. He was one of only 59 patients who were lucky enough to be
entered into a trial, among the many who join the "scramble for
cutting edge medications in a country where there aren't nearly enough of them to go around." The clinic caring for him "takes up the slack
for example, by enlisting its patients in drug studies."
"I felt myself stabilizing [he said]. I had the energy to go back
to work." However, his future,
Read all Rapid Responses